Results and epidemiological impact of directly observed therapy for tuberculosis;Resultados e impacto epidemiológico de una unidad de tratamiento directamente observado de la tuberculosis

Archivos de Bronconeumologia

Volumn 35, Issue 6, 1999, Pages 267-274

  Alcaide Megias J ^a   Pascual Torramade J ^b   Altet Gomez M N ^b   Maldonado Diaz De Losada J ^b   Lopez Espinosa F ^b   Salleras Sanmarti Ll ^b  

^a Depto de Sanidad y Seguridad Social   (Spain)

^b NONE

Author keywords

Directly observed therapy; Epidemiology; Tuberculosis

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HUMAN; INFANT; MALE; MIDDLE AGED; MORTALITY; NEWBORN; PATIENT COMPLIANCE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; SPAIN; TUBERCULOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN; TUBERCULOSIS;

EID: 0033145078     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-2896(15)30242-8     Document Type: Article

References (53)

1. World Health Organization. TB Program. TB, a global emergency: WHO report on the TB epidemicic. Ginebra: WHO/TB, 1994; 94-117.
2. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-226.
3. Kaye K, Frieden TR. Tuberculosis control: the relevance of classic principles in an era of acquired immunodeficiency syndrome and multidrug resistance. Epidemiol Rev 1996; 18: 52-63.
4. Bloom BR, Murray CJL. Tuberculosis: commentary on re-emergent killer. Science 1992; 257: 1.055-1.064.
5. Vall Mayans M, Maguire A, Miret M, Alcaide J, Parrón I, Casabona J. The spread of AIDS and re-emergence of tuberculosis in Catalonia, Spain. AIDS 1997; 11: 499-505.
6. Caminero Luna JA, Casal Roman M, Ausina Ruiz V, Pina Gutiérrez JM, Sauret Valet J. Diagnóstico de la tuberculosis (Normativas SEPAR). Arch Bronconeumol 1996; 132: 85-99.
7. Snider DE Jr, Roper WL. The new tuberculosis. N Engl J Med 1992; 326: 703-705.
8. Young KS, Wormser GP. The resurgence of tuberculosis. Scand J Infect Dis 1994; 93 (Supl): 9-19.
9. Caminero Luna JA. Situación actual de la tuberculosis en España [editorial]. Arch Bronconeumol 1994; 30: 371-374.
10. Alcaide Megías J, Altet Gómez MN. La tuberculosis infantil en España [editorial]. Arch Bronconeumol 1995; 31: 375-377.
11. Caylà JA, Jansà JM, Artacoz L. Estructura organizativa del tratamiento de la tuberculosis en un país endémico. En: Vidal Pla R, De March Ayuela P, editores. Tratamiento de la infección y enfermedad tuberculosa. Monografías clínicas en Neumología, n.o 4. Barcelona: Ed. Doyma, 1992; 69-76.
12. Cummings KC, Mohle-Boetani J, Royce SE, Chin DP. Movement of tuberculosis patients and the failure to complete antituberculosis treatment. Am J Respir Crit Care Med 1998; 157: 1.249-1.252.
13. Enarson DA, Grosse J, Mwinga A, Hersfield ES, O'Brien R, Cole S et al. Lancet Conference: The challenge tuberculosis: statements on global control and prevention. Lancet 1995; 346: 809-819.
14. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15.
15. a ed). Ginebra: Organización Mundial de la Salud WHO/TB/97.220, 1997.
16. Frieden TR, Fujiwara PI, Washko RM, Hanburg MA. Tuberculosis in New York city. Turning the tide [artículo especial]. N Engl J Med 1995; 333: 229-233.
17. Sumartojo E. When tuberculosis treatment fails. A social behavioral account of patient adherence. Am Rev Respir Dis 1993; 147: 1.311-1.320.
18. TB Programme. DOTS stop TB at the source: WHO report on the tuberculosis epidemic, 1995. Ginebra: World Health Organization, WHO/TB/95-183.
19. Domínguez García A, Alcaide Megías J, Trilla García A, Broquetas Dofiate JM, Verger Garau G, Prats Pastor G. Prevenció i control de la tuberculosi als centres sanitaris. Barcelona: Departament de Sanitat i Seguretat Social, Generalitat de Catalunya, 1997.
20. Earnest MA, Sbarbaro JA. Defining the issues: returning patients with tuberculosis to institutional settings. Clinical Infectious Dis 1995; 20: 497-500.
21. Pablos-Méndez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996; 276: 1.223-1.228.
22. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet 1995; 345: 1.545-1.548.
23. WHO. Antituberculosis drug resistance worldwide. Weekly Epidemiological Record 1998; 33: 249-254.
24. Frieden TR, Sterling T, Pablos-Méndez A, Kilbun JO, Cauthen GM, Dooley SW. The emergence of drug-resistent tuberculosis in New York City. N Engl J Med 1993; 328: 521-526.
25. Weis SE, Slocum PhC, Biais FX, King B, Nunn M, Matney B et al. The effect of directly observed therapy on the rates of drugs resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1.179-1.184.
26. Fujiwara PI, Larkin CH, Frieden TR. Directly observed therapy in New York city. History, implementation, results and challenges. En: Iseman MD, Huitt GA, editores. Tuberculosis. Clin Chest Med 1997; 18: 135-148.
27. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274: 945-951.
28. Kumaresan J. The DOTS strategy - what is it? Conference on global lung health and the 1997 annual meeting of the International Union Against Tuberculosis and Lung Disease. Paris, October 1997. Int J Tuberc Lung Dis 1997; 1 (Supl 1): 3-4.
29. Chaulk CP, Kaxandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis. JAMA 1998; 279: 943-948.
30. Bayer R, Dubler NN, Landesman S. The dual epidemics of tuberculosis and AIDS. Ethical and policy issues in screening and treatment. Am J Public Health 1993; 83: 649-654.
31. Iseman NM, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis. We can't afford not to try it. N Engl J Med 1993; 328: 576-578.
32. Floy C, Wilkinson D, Gilks Ch. Comparison of cost effectiveness of directly observed treatment (DOT) delivered treatment for tuberculosis: experience from rural South Africa. Br Med J 1997; 315: 1.407-1.411.
33. Moore RD, Chaulk CP, Griffiths R, Chaisson RE. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 1996; 154: 1.013-1.019.
34. Lobo Barroso CA, Pérez Escolano E. Tratamiento de la tuberculosis: cumplimiento, abandono y tratamientos supervisados. Arch Bronconeumol 1997; 33: 588-590.
35. Ngamvithayapong J, Ishikawa N, Yoshiyama T. Directly observed therapy for tuberculosis (DOT): international evidences and perspectives. Conference on Global Lung Health and the 1997 annual meeting of the International Union Against Tuberculosis and Lung Disease. Paris, October 1997. Int J Tuberc Lung Dis 1997; 1 (Supl 1): 68.
36. Sonnenberg P, Rors MB, Shearer SCPM, Murray J. The effect of dosage cards on compliance with directly observed tuberculosis therapy in hospital. Int J Tuberc Lung Dis 1998; 2: 168-171.
37. Programa de prevenció i control de la tuberculosi. Explotació de les dades del registre de malalts. Any 1992. Barcelona: Direcció General de Salut Pública del Departement de Sanitat i Seguretat Social, Generalitat de Catalunya, 1995.
38. Programa de prevenció i control de la tuberculosi. La tuberculosi a Catalunya. BEC 1996; 18: 160-162.
39. Programa de prevenció i control de la tuberculosi. La tuberculosi a Catalunya. BEC 1998; 19: 35-38.
40. Dlodlo RA. Tuberculosis treatment outcome in Bulawayo, Zimbabwe in 1994-1996. Conference on Global Lung Health and the 1997 Annual Meeting of the International Union Against Tuberculosis and Lung Disease. Paris, October 1997. Int J Tuber Lung Dis 1997; 1 (Supl 1): 68.
41. Olewe MA. Young males tend to default from directly observed treatment, short course (DOTS). Conference on Global Lung Health and the 1997 Annual Meeting of the International Union Against Tuberculosis and Lung Disease. Paris, October 1997. Int J Tuberc Lung Dis 1997; 1 (Supl 1): 85.
42. Yáñez-Velasco LB, Guadalupe Q, Rodríguez J. Use of DOTS in pilot areas of Mexico. Conference on Global Lung Health and the 1997 Annual Meeting of the International Union Against Tuberculosis and Lung Disease. Paris, October 1997. Int J Tuberc Lung Dis 1997; 1 (Supl 1): 68.
43. Shluger N, Ciatoli C, Cohen D, Johson H, Rom WN. Comprehensive tuberculosis control for patients at high risk for noncompliance. Am J Respir Crit Care Med 1995; 151: 1.486-1.490.
44. Noval PY, Kong Kim S, Team B, Ahn DI, Blanc L. DOTS in Cambodia. Int J Tuberc Lung Dis 1998; 2: 44-51.
45. Smirnoff M, Goldberg R, Indyk L, Adler JJ. Directly observed therapy in an inner city hospital. Int J Tuberc Lung Dis 1998; 2: 134-139.
46. Salomon N, Perlman DC, Rubinstein A, Mandelman DD, McKinley FW, Yancovitz SS. Implementation of universal directly observed therapy at a New York city hospital and evaluation of an out-patients directly observed therapy program. Int J Tuberc Lung Dis 1997; 1: 397-404.
47. Díez E, Clavería J, Serra T, Caylà JA, Jansà JM, Pedro R et al. Evaluation of a social health intervention among homeless tuberculosis patients. Tubercle Lung Dis 1996; 77: 420-424.
48. CEESCAT. Vigilància epidemiològica de la sida a Catalunya. Situació fins al 30 de juny de 1998. Informe trimestral 22-7-98.
49. Farjas Abadía P. Estrategia intersectorial frente a la tuberculosis: experiencia de Galicia. Madrid: I Jornadas Internacionales sobre programas de prevención y control de la tuberculosis en la Comunidad de Madrid. Libro de Ponencias y Comunicaciones, 1998.
50. Castell C. El programa para el control de la tuberculosis en la Comunidad Autónoma del País Vasco. Taller sobre programas de control de la tuberculosis. Barcelona: Unidad de Investigación en Tuberculosis de Barcelona, 1998.
51. Farberow NL. Noncompliance as indirect self-destructive behaviour. En: Gerber KE, Nehemis AM, editores. Compliance. The dilemma of the chronically III. Nueva York: Springer, 1986.
52. Alcaide J, Altet MN, Pascual J. Terapia de observación directa de la tuberculosis. FMC 1996; 3: 506-513.
53. Oscherwitz T, Tulsky JP, Roger S, Sciortino S, Alpers A, Royce S et al. Detention of persistently nonadherent patients with tuberculosis. JAMA 1997; 278: 843-846.